TG Therapeutics, Inc.
US ˙ NasdaqCM ˙ US88322Q1085

SecurityTGTX / TG Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership251,643 shares
Latest Disclosed Value $ 9,056,631
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 5.76% increase in ownership of TGTX / TG Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 251,643 shares of TG Therapeutics, Inc. (US:TGTX) valued at $9,056,632 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 237,934 shares of TG Therapeutics, Inc.. This represents a change in shares of 5.76% during the quarter. The current value of the position is $10,105,983 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP TG Therapeutics EC US88322Q1085 251,643 13,709 5.76 9,057 -3.46 0.2034
2025-05-28 2025-03-31 NP TG Therapeutics EC US88322Q1085 237,934 2,526 1.07 9,382 32.41 0.2250
2025-02-25 2024-12-31 NP TG Therapeutics EC US88322Q1085 235,408 -38,594 -14.09 7,086 10.56 0.1547
2024-11-26 2024-09-30 NP TG Therapeutics EC US88322Q1085 274,002 11,950 4.56 6,409 37.48 0.1212
2024-08-26 2024-06-30 NP TG Therapeutics EC US88322Q1085 262,052 17,232 7.04 4,662 25.19 0.0949
2024-05-28 2024-03-31 NP TG Therapeutics EC US88322Q1085 244,820 -6,127 -2.44 3,724 -13.14 0.0777
2024-02-26 2023-12-31 NP TG Therapeutics EC US88322Q1085 250,947 18,144 7.79 4,286 120.25 0.0915
2023-11-28 2023-09-30 NP TG Therapeutics EC US88322Q1085 232,803 -4,218 -1.78 1,946 -66.94 0.0508
2023-08-25 2023-06-30 NP TG Therapeutics EC US88322Q1085 237,021 25,058 11.82 5,888 84.72 0.1396
2023-05-26 2023-03-31 NP TG Therapeutics EC US88322Q1085 211,963 3,210 1.54 3,188 29.08 0.0849
2023-02-24 2022-12-31 NP TG Therapeutics EC US88322Q1085 208,753 1,643 0.79 2,470 101.39 0.0679
2022-11-25 2022-09-30 NP TG Therapeutics EC US88322Q1085 207,110 -17,905 -7.96 1,226 28.24 0.0351
2022-08-25 2022-06-30 NP TG Therapeutics EC US88322Q1085 225,015 22,157 10.92 956 -50.44 0.0264
2022-05-26 2022-03-31 NP TG Therapeutics EC US88322Q1085 202,858 4,145 2.09 1,929 -48.90 0.0449
2022-02-25 2021-12-31 NP TG Therapeutics EC US88322Q1085 198,713 3,107 1.59 3,776 -42.00 0.0819
2021-11-24 2021-09-30 NP TG Therapeutics EC US88322Q1085 195,606 543 0.28 6,510 -13.97 0.1434
2021-08-26 2021-06-30 NP TG Therapeutics EC US88322Q1085 195,063 10,562 5.72 7,566 -14.91 0.1623
2021-05-27 2021-03-31 NP TG Therapeutics EC US88322Q1085 184,501 4,590 2.55 8,893 -4.98 0.2017
2021-02-25 2020-12-31 NP TG Therapeutics EC US88322Q1085 179,911 -1,419 -0.78 9,359 92.87 0.2398
2020-11-25 2020-09-30 NP TG Therapeutics EC US88322Q1085 181,330 17,761 10.86 4,852 52.29 0.1557
2020-08-27 2020-06-30 NP TG Therapeutics EC US88322Q1085 163,569 21,794 15.37 3,186 128.39 0.1042
2020-06-01 2020-03-31 NP TG Therapeutics EC US88322Q1085 141,775 3,093 2.23 1,395 -9.36 0.0570
2020-02-27 2019-12-31 NP TG Therapeutics EC 88322Q108 138,682 18,821 15.70 1,539 128.68 0.0463
2019-11-27 2019-09-30 NP TG Therapeutics EC US88322Q1085 119,861 119,861 673 0.0222
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.